Antisoma PLC has adopted a new clinical programme around Therex, a product based on the humanised monoclonal antibody huHMFG1 aiming to treat breast cancer. Originally developed by the Imperial Cancer Research Fund (ICRF), Therex is in a Phase I clinical study. The antibody targets most common epithelial cancers, including breast, lung, ovarian, gastric and colorectal Read more about Antisoma Adopts Therex From Imperial Cancer Research Fund[…]